174 related articles for article (PubMed ID: 19874319)
1. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype.
Lebeau S; Müller R; Masouyé I; Hertl M; Borradori L
Clin Exp Dermatol; 2010 Jun; 35(4):366-72. PubMed ID: 19874319
[TBL] [Abstract][Full Text] [Related]
2. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
[TBL] [Abstract][Full Text] [Related]
3. Five Japanese cases of antidesmoglein 1 antibody-positive and antidesmoglein 3 antibody-negative pemphigus with oral lesions.
Koga H; Ohyama B; Tsuruta D; Ishii N; Hamada T; Dainichi T; Natsuaki Y; Sogame R; Fukuda S; Karashima T; Tada J; Yamashiro M; Uezato H; Chan PT; Hashimoto T
Br J Dermatol; 2012 May; 166(5):976-80. PubMed ID: 22242828
[TBL] [Abstract][Full Text] [Related]
4. Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity.
Hallaji Z; Mortazavi H; Lajevardi V; Tamizifar B; AmirZargar A; Daneshpazhooh M; Chams-Davatchi C
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):275-80. PubMed ID: 19709345
[TBL] [Abstract][Full Text] [Related]
5. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus.
Ohyama M; Amagai M; Hashimoto T; Nousari HC; Anhalt GJ; Nishikawa T
J Am Acad Dermatol; 2001 Apr; 44(4):593-8. PubMed ID: 11260531
[TBL] [Abstract][Full Text] [Related]
6. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
[TBL] [Abstract][Full Text] [Related]
7. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus.
Mentink LF; de Jong MC; Kloosterhuis GJ; Zuiderveen J; Jonkman MF; Pas HH
Br J Dermatol; 2007 Apr; 156(4):635-41. PubMed ID: 17263817
[TBL] [Abstract][Full Text] [Related]
8. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.
Abasq C; Mouquet H; Gilbert D; Tron F; Grassi V; Musette P; Joly P
Arch Dermatol; 2009 May; 145(5):529-35. PubMed ID: 19451496
[TBL] [Abstract][Full Text] [Related]
9. Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients.
Cozzani E; Di Zenzo G; Riva S; Calabresi V; Sera F; Drosera M; Parodi A
Eur J Dermatol; 2013; 23(1):40-8. PubMed ID: 23400331
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.
Femiano F
Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959
[TBL] [Abstract][Full Text] [Related]
11. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris.
Müller R; Svoboda V; Wenzel E; Müller HH; Hertl M
Exp Dermatol; 2008 Jan; 17(1):35-43. PubMed ID: 18095943
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus.
Yoshida K; Takae Y; Saito H; Oka H; Tanikawa A; Amagai M; Nishikawa T
J Am Acad Dermatol; 2005 May; 52(5):839-45. PubMed ID: 15858475
[TBL] [Abstract][Full Text] [Related]
13. Analysis of immunological profile, clinical features and response to treatment in pemphigus.
Bardazzi F; Balestri R; Ismaili A; LA Placa M; Barisani A; Patrizi A
G Ital Dermatol Venereol; 2017 Dec; 152(6):569-577. PubMed ID: 27352177
[TBL] [Abstract][Full Text] [Related]
14. Low pathogenicity of anti-desmoglein 3 immunoglobulin G autoantibodies contributes to the atypical clinical phenotypes in pemphigus.
Saleh MA; Hashimoto R; Kase Y; Amagai M; Yamagami J
J Dermatol; 2015 Jul; 42(7):685-9. PubMed ID: 25914046
[TBL] [Abstract][Full Text] [Related]
15. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris.
Harman KE; Gratian MJ; Shirlaw PJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2002 Apr; 146(4):684-7. PubMed ID: 11966706
[TBL] [Abstract][Full Text] [Related]
16. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients.
Schmidt E; Dähnrich C; Rosemann A; Probst C; Komorowski L; Saschenbrecker S; Schlumberger W; Stöcker W; Hashimoto T; Bröcker EB; Recke A; Rose C; Zillikens D
Exp Dermatol; 2010 May; 19(5):458-63. PubMed ID: 20163452
[TBL] [Abstract][Full Text] [Related]
17. Recalcitrant facial pemphigus vulgaris: correlation of skin lesions with the ratio of antidesmoglein antibodies 1 and 3.
Fujii M; Honma M; Iinuma S; Kaneta K; Komatsu S; Sato K; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Apr; 36(3):284-7. PubMed ID: 21418270
[TBL] [Abstract][Full Text] [Related]
18. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
[TBL] [Abstract][Full Text] [Related]
19. Orodigital pemphigus vulgaris: a pathogenic role of anti-desmoglein-3 autoantibodies in pemphigus paronychia?
Laffitte E; Panizzon RG; Borradori L
Dermatology; 2008; 217(4):337-9. PubMed ID: 18799879
[TBL] [Abstract][Full Text] [Related]
20. Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission.
Kwon EJ; Yamagami J; Nishikawa T; Amagai M
J Eur Acad Dermatol Venereol; 2008 Sep; 22(9):1070-5. PubMed ID: 18410336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
